Last year, the drug-maker paid a $650 million settlement, or an average of $150,000 per case, to end the litigation. Similar accusations were made against Boehringer Ingelheim in 9,00 Pradaxa lawsuits. Plaintiffs accuse drug-makers of aggressively pushing Xarelto without adequately warning about the risk of uncontrollable bleeding. As the popularity of Pradaxa skyrocketed, so did the number of adverse events involving uncontrollable internal bleeding and death.Įven more problematic, Pradaxa was quickly followed by other blood-thinners without reversal agents - Xarelto, Eliquis, and Savaysa.Ībout 1,700 lawsuits have been filed by people who took Xarelto and experienced severe bleeding.
However, until today, Pradaxa had no reversal agent. When Pradaxa hit the market in 2010, it was promoted as superior to warfarin. Warfarin is a cumbersome drug, but its one advantage is that a dose of Vitamin K reverses its blood-thinning effects.
Pradaxa was the first once-daily pill designed to replace warfarin (Coumadin), a blood-thinner that had been on the market since the 1950s. It is approved for “ emergency or life-threatening situations when bleeding can’t be controlled.” In a study of 123 patients who needed emergency surgery or were bleeding uncontrollably, Praxbind stopped the effects of Pradaxa within four hours in 89% of patients, according to the FDA. OctoBoehringer Ingelheim has been granted FDA approval for Praxbind, an intravenous (IV) antidote to the blood-thinning drug Pradaxa.
0 kommentar(er)
